ACHILLES THERAPEUTICS PLC

Analyst Reco. Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Market Closed - Nasdaq Other stock markets 21:30:00 25/06/2024 BST			5-day change	1st Jan Change
0.8681 ^USD	+1.43%		-3.01%	-2.35%

05-22	Achilles Therapeutics Collaborating With Arcturus Therapeutics to Evaluate mRNA Personalized Cancer Vaccines	MT
05-22	Achilles Therapeutics plc Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8	04-05	MT
Chardan Capital Adjusts Achilles Therapeutics Price Target to $6 From $11, Maintains Buy Rating	04-05	MT
BofA Securities Downgrades Achilles Therapeutics to Underperform From Buy, Price Target is $0.50	12-14	MT
Chardan Trims Price Target on Achilles Therapeutics to $11 From $12, Keeps Buy Rating	11/05/23	MT
Chardan Adjusts Price Target on Achilles Therapeutics to $12 From $17, Keeps Buy Rating	08/03/23	MT
Oppenheimer Downgrades Achilles Therapeutics to Perform From Outperform on Lack of Clear Benefits to Cancer Drug Over Peer Treatment, Removes PT From $19	07/12/22	MT
Piper Sandler Cuts Price Target on Achilles Therapeutics to $8 From $10, Keeps Overweight Rating	07/12/22	MT
Chardan Cuts Price Target on Achilles Therapeutics to $17 From $20, Affirms Buy Rating	07/12/22	MT
Piper Sandler Adjusts Price Target on Achilles Therapeutics to $10 From $17, Reiterates Overweight Rating	31/05/22	MT
Oppenheimer Adjusts Achilles Therapeutics Price Target to $19 From $23, Maintains Outperform Rating	02/03/22	MT
ACHILLES THERAPEUTICS : JP Morgan Initiates Achilles Therapeutics at Underweight Rating With $11 Price Target	26/04/21	MT
ACHILLES THERAPEUTICS : Oppenheimer Initiates Coverage on Achilles Therapeutics With Outperform Rating, $23 Price Target	26/04/21	MT
ACHILLES THERAPEUTICS : Chardan Initiates Coverage on Achilles Therapeutics With Buy Rating, $27 Price Target	26/04/21	MT
ACHILLES THERAPEUTICS : BofA Securities Starts Achilles Therapeutics at Buy With $20 Price Target	26/04/21	MT
ACHILLES THERAPEUTICS : Piper Sandler Starts Achilles Therapeutics at Overweight With $25 Price Target	26/04/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Our Free Content Help you Secure and Increase the Performance of Your Investments

Securing my Investments

fermer